Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer

Dai, 2017, (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1, J. Exp. Clin. Cancer Res., 36, 120, 10.1186/s13046-017-0584-3 Duan, 2018, Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo, Int. J. Nanomedicine, 13, 1831, 10.2147/IJN.S153795 Eloy, 2017, Immunoliposomes: a review on functionalization strategies and targets for drug delivery, Colloids Surf B Biointerfaces, 159, 454, 10.1016/j.colsurfb.2017.07.085 FDA, U.S., 2013. Approved Drugs: Afatinib.pharmacology/toxicology NDA review and evaluation, in: Dubravka Kufrin , S.L.W. (Ed.). FDA, U.S., 2018. SUPPLEMENT APPROVAL. Gettinger, 2015, Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, J. Clin. Oncol., 33, 2004, 10.1200/JCO.2014.58.3708 Gazzah, 2018, A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours, Eur. J. Cancer, 104, 1, 10.1016/j.ejca.2018.07.011 Gralla, 2014, An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients, J. Thorac. Oncol., 9, 1243, 10.1097/JTO.0000000000000244 Hata, 2015, Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI, J. Thorac. Oncol., 10, 1553, 10.1097/JTO.0000000000000647 Hioki, 2010, Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature, Biol. Pharm. Bull., 33, 1466, 10.1248/bpb.33.1466 Janjigian, 2014, Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations, Cancer Discov., 4, 1036, 10.1158/2159-8290.CD-14-0326 Johnson, 2011, Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib, J. Thorac. Oncol., 6, 1128, 10.1097/JTO.0b013e3182161508 Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 352, 786, 10.1056/NEJMoa044238 Kosaka, 2006, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib, Clin. Cancer Res., 12, 5764, 10.1158/1078-0432.CCR-06-0714 Ma, 2015, Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab, Int. J. Nanomed., 10, 2173, 10.2147/IJN.S77152 Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65, 271, 10.1016/S0168-3659(99)00248-5 Miao, 2016, Fluorescent aptasensor for chloramphenicol detection using DIL-encapsulated liposome as nanotracer, Biosens. Bioelectron., 81, 454, 10.1016/j.bios.2016.03.034 Miller, 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, Lancet Oncol., 13, 528, 10.1016/S1470-2045(12)70087-6 Morgillo, 2016, Mechanisms of resistance to EGFR-targeted drugs: lung cancer, ESMO Open, 1, 10.1136/esmoopen-2016-000060 Mortensen, 2013, Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme, J. Drug. Deliv., 2013, 10.1155/2013/209205 Riely, 2007, Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus, Clin. Cancer Res., 13, 5150, 10.1158/1078-0432.CCR-07-0560 Sequist, 2010, Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer, J. Clin. Oncol., 28, 3076, 10.1200/JCO.2009.27.9414 Sequist, 2010, Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer, J. Clin. Oncol., 28, 4953, 10.1200/JCO.2010.30.8338 Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J. Clin. Oncol., 31, 3327, 10.1200/JCO.2012.44.2806 Smith, 2013, Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs, Vet Anaesth Analg, 40, 537, 10.1111/vaa.12042 Torino, 2009, Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy, Nat. Rev. Clin. Oncol., 6, 219, 10.1038/nrclinonc.2009.4 Uchibori, 2017, Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer, Nat. Commun., 8, 14768, 10.1038/ncomms14768 Vincenzi, 2008, The biological properties of cetuximab, Crit. Rev. Oncol. Hematol., 68, 93, 10.1016/j.critrevonc.2008.07.006 Wang, 2016, Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(D, L-lactic acid), Acta Biomater., 29, 248, 10.1016/j.actbio.2015.10.017 Wang, 2016, Magnetically and pH dual responsive dendrosomes for tumor accumulation enhanced folate-targeted hybrid drug delivery, J. Control. Release, 232, 161, 10.1016/j.jconrel.2016.04.015 Wecker, 2018, Afatinib, Recent Results Cancer Res., 211, 199, 10.1007/978-3-319-91442-8_14 Yang, 2013, Diarrhea associated with afatinib: an oral ErbB family blocker, Expert Rev. Anticancer Ther., 13, 729, 10.1586/era.13.31 Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin. Cancer Res., 19, 2240, 10.1158/1078-0432.CCR-12-2246 Yu, 2013, Targeted therapies: Afatinib–new therapy option for EGFR-mutant lung cancer, Nat. Rev. Clin. Oncol., 10, 551, 10.1038/nrclinonc.2013.154